Replies to post #460 on Fate Therapeutics Inc (FATE)

[jondoeuk]

They knockout SOCS1, CISH, BIM and FAS. Nothing about the proprietary signal converter or design of the CAR. As for HLA-E, it makes little sense to me as 50-90% of the human population are CMV+ (NKG2C+ adaptive NKs target HLA-E+ cells) https://onlinelibrary.wiley.com/doi/10.1002/rmv.2034

Also, work on iPSC-derived ab T-cells is ongoing.

[jondoeuk]

A post on LinkedIn (by Alex Shih-Min Huang who is VP, Head of Cell Therapy at BGNE): ''Though our very first experiment was initiated only 2.5 years ago amidst ongoing laboratory construction and pandemic, fast forward to this day, we have already 1) generated a proprietary, well-characterized GMP grade iPSC clone collection designated for our future gd T and ab T cellular products, 2) established our unique efficient, enrichment-free, feeder-free methodologies that deliver impressively high purity and high expansion fold for our iPSC derived gd T and iPSC derived CD8 ab T platforms, and 3) engineered proprietary genetic elements that further enhance the longevity and potential efficacy of our effector cell populations. Our platforms are designed to allow plug-and-play for a variety of CAR-T and TCR-T cell therapies with potential to address unmet needs in diverse indications.''

[jondoeuk]

''Nova Biotechnology (Suzhou) Co., Ltd. (Nova Biosciences), a R&D company focused on TCR-T immune cell therapies for solid tumors, announced that it has signed a non-exclusive license agreement with BeiGene to license the rights to an antigen-specific TCR molecule developed by BeiGene for the development of next-generation generic cell therapies based on the iPSC platform.'' https://mp.weixin.qq.com/s/x8xur0IDjEY5KGizwoOZAA